Table 1.
Baseline clinical characteristics.
| Control (n = 24) |
Spironolactone (n = 25) |
p-Value | |
|---|---|---|---|
| Age (years) | 64 ± 12 | 66 ± 10 | 0.540 |
| Gender (male/female) | 10/14 | 14/11 | 0.326 |
| Body mass index (kg/m2) | 26.0 ± 3.2 | 26.0 ± 3.3 | 0.965 |
| Smoking (n) | 1 | 0 | 0.289 |
| Diabetes (n) | 6 | 4 | 0.445 |
| Hyperlipidemia (n) | 10 | 8 | 0.493 |
| CAD (n) | 3 | 5 | 0.488 |
| History of AF (n) | 3 | 6 | 0.431 |
| NYHA class II/III (n/n) | 16/8 | 14/11 | 0.454 |
| Aspirin (n) | 4 | 6 | 0.534 |
| CCB (n) | 16 | 21 | 0.165 |
| β-blocker (n) | 20 | 21 | 0.951 |
| ACEI/ARB (n) | 7 | 3 | 0.142 |
| Diuretics (n) | 14 | 15 | 0.908 |
| Digitalis (n) | 0 | 0 | |
| AAA (n) | 2 | 5 | 0.252 |
| Statins (n) | 5 | 6 | 0.796 |
| QRS duration (ms) | 88 ± 8 | 88 ± 8 | 0.982 |
AAA, antiarrhythmic agent; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin II receptor blocker; AF, atrial fibrillation; CAD, coronary artery disease; CCB, calcium channel blocker; NYHA, New York Heart Association.